TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. (Nasdaq: TELA) on April 22, 2021, covering events occurring on April 16, 2021. The Company is an emerging growth company incorporated in Delaware, focused on developing novel therapies for cancer and other diseases.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
The primary material change reported is the departure of a director:
- Adele Oliva, a member of the Board of Directors, notified the Company of her intent not to stand for re-election at the 2021 Annual Meeting of Stockholders.
- Her term will conclude upon the end of the Annual Meeting scheduled for June 2, 2021.
- Ms. Oliva is also resigning from her roles as member and chair of the Nominating and Corporate Governance Committee.
- The Company stated that her resignation did not result from any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It is limited to the announcement of the director's departure and the Company's expression of gratitude for her service.
Key Facts for Investor Verification
- Verify the date of the 2021 Annual Meeting of Stockholders (stated as June 2, 2021) to confirm the exact end date of Ms. Oliva's term.
- Check subsequent filings to determine if a replacement director was nominated or elected to fill the vacancy.
- Confirm the composition of the Nominating and Corporate Governance Committee following Ms. Oliva's resignation from the chair and member roles.